CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 43 enrolled
Drug / intervention
Experimental Daily Defense Serum A +4 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03233009
NCT03233009N/ACompleted

A Human Subject 24 Hour Patch Test to Assess the Irritation Potential of Four Skin Serum Products

GlaxoSmithKline·interventional·Posted Jul 28, 2017·Updated Jan 16, 2019

In Brief

A clinical study evaluating Experimental Daily Defense Serum A, Experimental Daily Defense Serum C, and 3 other interventions for Skin Care. Completed, enrolled 43 participants across 2 sites.

Detailed Summary

To assess the irritation potential of four prototype daily defense serum formulations after 24 (± 2) hours under semi-occlusive patch application to the skin of healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Care
CountriesBrazil
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJul 28, 2017
Enrollment StartMay 22, 2017
Primary CompletionMay 26, 2017
TodayJul 2, 2026
Enrollment to primary: 4 daysPosted 8.9 years ago

Interventions

Experimental Daily Defense Serum Aother

Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).

Experimental Daily Defense Serum Cother

Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).

Experimental Daily Defense Serum Gother

Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).

Experimental Daily Defense Serum Nother

Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).

Saline Solution Sodium Chlorideother

Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).